drugset / Trial / NCT02405364
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction
Phase 2
Completed
46 enrolled
University Hospital, Toulouse
Celgene Corporation · collabOnyx Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose is to determine whether induction and consolidation treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further investigation in clinical trials.
Timeline
- Start
- 2014-02
- Primary completion
- 2019-11-25
- Completion
- 2019-11-25
Publications
- Results Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet L, Escoffre-Barbe M, Mariette C, Benboubker L, Caillot D, Sonntag C, Touzeau C, Dupuis J, Moreau P, Leleu X, Facon T, Hebraud B, Corre J, Attal M. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 2021 Jul 15;138(2):113-121. doi: 10.1182/blood.2021010744.
- Landgren O, Kazandjian D, Roussel M, Jasielec J, Dytfeld D, Anderson A, Kervin TA, Iskander K, McFadden I, Jakubowiak AJ. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 Oct;63(10):2413-2421. doi: 10.1080/10428194.2022.2068001. Epub 2022 May 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 36 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Melphalan | Small molecule | — | — |